Clinical trials have reported that BBR treatment reduced the levels of the cardiovascular risk indicators, such as LDL, and apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratios, and improved the quality of life in congestive heart failure patients in combination with conventional therapy [91, 92]. The gene discussed is APOB; the disease is congestive heart failure.